Stockbridge Partners LLC Has $294.75 Million Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Stockbridge Partners LLC trimmed its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 566,583 shares of the medical research company's stock after selling 10,000 shares during the period. Thermo Fisher Scientific accounts for approximately 6.3% of Stockbridge Partners LLC's holdings, making the stock its 9th largest holding. Stockbridge Partners LLC owned approximately 0.15% of Thermo Fisher Scientific worth $294,753,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Stonegate Investment Group LLC increased its stake in shares of Thermo Fisher Scientific by 0.3% during the 4th quarter. Stonegate Investment Group LLC now owns 6,788 shares of the medical research company's stock worth $3,531,000 after purchasing an additional 18 shares during the last quarter. Semus Wealth Partners LLC increased its position in Thermo Fisher Scientific by 4.0% during the fourth quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company's stock worth $245,000 after buying an additional 18 shares during the last quarter. KRS Capital Management LLC raised its stake in Thermo Fisher Scientific by 1.5% in the fourth quarter. KRS Capital Management LLC now owns 1,317 shares of the medical research company's stock valued at $685,000 after buying an additional 20 shares during the period. Revolve Wealth Partners LLC boosted its stake in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after acquiring an additional 20 shares during the period. Finally, Evernest Financial Advisors LLC increased its holdings in shares of Thermo Fisher Scientific by 4.0% during the 4th quarter. Evernest Financial Advisors LLC now owns 521 shares of the medical research company's stock worth $271,000 after acquiring an additional 20 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the transaction, the executive vice president now owns 23,167 shares of the company's stock, valued at $9,960,188.31. This represents a 1.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Michael A. Boxer sold 3,775 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the sale, the senior vice president now owns 10,816 shares in the company, valued at approximately $5,759,736.32. This trade represents a 25.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 14,075 shares of company stock worth $7,305,942 in the last three months. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Price Performance

NYSE:TMO traded down $0.45 during mid-day trading on Tuesday, reaching $413.47. The stock had a trading volume of 2,141,884 shares, compared to its average volume of 1,845,527. Thermo Fisher Scientific Inc. has a 12 month low of $390.50 and a 12 month high of $627.88. The stock has a market capitalization of $156.08 billion, a PE ratio of 25.01, a P/E/G ratio of 2.99 and a beta of 0.82. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The stock has a 50-day simple moving average of $449.99 and a two-hundred day simple moving average of $508.22.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. During the same quarter last year, the company posted $5.11 EPS. The company's revenue for the quarter was up .2% compared to the same quarter last year. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were paid a $0.43 dividend. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.42%. The ex-dividend date was Friday, March 14th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. UBS Group decreased their price objective on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a report on Thursday, April 24th. Morgan Stanley raised their price objective on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an "overweight" rating in a research report on Friday, January 31st. Barclays dropped their price target on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the stock a "buy" rating in a research report on Wednesday, April 23rd. Finally, Evercore ISI reduced their target price on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Five investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, Thermo Fisher Scientific has an average rating of "Moderate Buy" and an average target price of $607.43.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.